Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?
作者信息
Premkumar Vikram, Comenzo Raymond, Lentzsch Suzanne
机构信息
Division of Hematology/Oncology, Columbia University Medical Center, New York, NY.
Division of Hematology/Oncology, Tufts Medical Center, Boston, MA.
出版信息
Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):686-688. doi: 10.1016/j.clml.2019.07.003. Epub 2019 Jul 15.
Abstract
摘要
相似文献
1
Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?维奈托克在免疫球蛋白轻链淀粉样变性中的应用：这是开始还是结束？
Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):686-688. doi: 10.1016/j.clml.2019.07.003. Epub 2019 Jul 15.
2
Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone.维奈托克在一名接受环磷酰胺、硼替佐米和地塞米松治疗后病情稳定的免疫球蛋白轻链淀粉样变性患者中诱导了完全缓解。
Haematologica. 2018 Mar;103(3):e135-e137. doi: 10.3324/haematol.2017.183749. Epub 2018 Jan 19.
3
Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: Less is more?维奈托克单药治疗在一位虚弱的难治性 AL 淀粉样变性患者中诱导出快速和持续的缓解：少即是多？
Int J Hematol. 2020 Aug;112(2):234-237. doi: 10.1007/s12185-020-02857-2. Epub 2020 Mar 23.
4
Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.维奈托克联合硼替佐米、地塞米松和达雷妥尤单抗治疗多发性骨髓瘤
Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):e339-e343. doi: 10.1016/j.clml.2018.06.003. Epub 2018 Jun 18.
5
Venetoclax induces profound and sustained responses in patients with relapsed/refractory light-chain amyloidosis.维奈托克在复发/难治性轻链淀粉样变性患者中可诱导深度且持久的反应。
Br J Haematol. 2021 May;193(3):674-677. doi: 10.1111/bjh.17380. Epub 2021 Mar 13.
6
Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis.心脏移植后三发性难治性免疫球蛋白轻链淀粉样变患者对单药 Bcl-2 抑制剂 Venetoclax 的快速完全缓解。
Acta Haematol. 2020;143(5):500-503. doi: 10.1159/000504355. Epub 2020 Jan 2.
7
Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.维奈托克联合硼替佐米及地塞米松用于既往接受过大量治疗的无t(11;14)的晚期骨髓瘤患者：一项真实世界队列研究
Hematol Oncol. 2020 Aug;38(3):412-414. doi: 10.1002/hon.2736. Epub 2020 Apr 23.
8
A man with chest tightness and burning limbs.
BMJ. 2017 May 11;357:j1979. doi: 10.1136/bmj.j1979.
9
Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).维奈克拉联合达雷妥尤单抗可使一名患有t(11;14)的AL淀粉样变性患者出现血液学完全缓解及器官反应。
Amyloid. 2019 Sep;26(3):173-174. doi: 10.1080/13506129.2019.1615428. Epub 2019 Jun 22.
10
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study.达雷妥尤单抗联合硼替佐米及地塞米松治疗新诊断的2004版梅奥分期IIIA或IIIB期轻链型淀粉样变性的疗效与安全性：一项前瞻性II期研究
Haematologica. 2024 Jul 1;109(7):2355-2358. doi: 10.3324/haematol.2024.285145.
引用本文的文献
1
Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation.维奈托克联合CyBorD诱导疗法及维奈托克维持治疗伴t(11;14)易位的免疫球蛋白轻链淀粉样变性
Curr Oncol. 2025 Jan 26;32(2):63. doi: 10.3390/curroncol32020063.
2
Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.靶向 Venetoclax 治疗 t(11;14)多发性骨髓瘤：来自七个匈牙利中心的真实世界数据。
Pathol Oncol Res. 2022 Feb 28;28:1610276. doi: 10.3389/pore.2022.1610276. eCollection 2022.
3
Current Updates on the Management of AL Amyloidosis.AL淀粉样变性病管理的最新进展
J Hematol. 2021 Aug;10(4):147-161. doi: 10.14740/jh866. Epub 2021 Aug 4.
4
Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.免疫球蛋白轻链淀粉样变性的遗传发病机制：基本特征及临床应用
Exp Hematol Oncol. 2021 Jul 20;10(1):43. doi: 10.1186/s40164-021-00236-z.
5
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.维奈托克可诱导 t(11;14)复发/难治性 AL 淀粉样变性的深度血液学缓解。
Blood Cancer J. 2021 Jan 11;11(1):10. doi: 10.1038/s41408-020-00397-w.
6
Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses.治疗蛋白质错误折叠疾病：针对全身性淀粉样变性的治疗成功案例
Front Pharmacol. 2020 Jul 10;11:1024. doi: 10.3389/fphar.2020.01024. eCollection 2020.
7
Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.复发/难治性系统性轻链（AL）淀粉样变性的治疗选择：当前观点
J Blood Med. 2019 Oct 23;10:373-380. doi: 10.2147/JBM.S183857. eCollection 2019.
本文引用的文献
1
Use of novel therapies in the treatment of light chain amyloidosis.新型疗法在轻链淀粉样变性治疗中的应用。
Blood Rev. 2019 Sep;37:100581. doi: 10.1016/j.blre.2019.05.005. Epub 2019 May 22.
2
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Venetoclax 作为靶向治疗复发/难治性 t(11;14)多发性骨髓瘤的疗效。
Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.
3
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.硼替佐米和地塞米松联合维奈托克治疗复发/难治性多发性骨髓瘤显示出良好的疗效和可接受的安全性。
Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.
4
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.接受大剂量治疗的骨髓瘤患者中t(11;14)(q13;q32)、t(4;14)(p16.3;q32)和-17p13的临床意义
Blood. 2005 Oct 15;106(8):2837-40. doi: 10.1182/blood-2005-04-1411. Epub 2005 Jun 23.
Zotero 插件